You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FLT3-ITD positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

Co-existing Mutations on Sorafenib Maintenance Therapy After

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
May 30, 2022

Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

Terminated
Has Results
  • Leukemia, Myeloid, Acute
  • Denver, Colorado
  • +4 more
May 10, 2022

Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
  • Cincinnati, Ohio
  • +18 more
Jan 20, 2023

Acute Myeloid Leukemia With FLT3/ITD Mutation Trial (XY0206, Salvage Chemotherapy)

Not yet recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • (no location specified)
May 24, 2023

Acute Myeloid Leukemia Trial (Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy)

Withdrawn
  • Acute Myeloid Leukemia
  • (no location specified)
May 18, 2022

FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid

Not yet recruiting
  • Acute Myeloid Leukemia
    • (no location specified)
    May 17, 2022

    Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

    Not yet recruiting
    • Leukemia, Acute Myeloid (AML)
    • (no location specified)
    Oct 16, 2022

    Acute Myeloid Leukemia With FLT3/ITD Mutation Trial in Tampa (Gilteritinib, Vyxeos)

    Suspended
    • Acute Myeloid Leukemia With FLT3/ITD Mutation
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 11, 2022

    Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)

    Terminated
    Has Results
    • Acute Myeloid Leukemia
    • Los Angeles, California
    • +7 more
    Mar 14, 2022

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia

    Active, not recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +36 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jan 23, 2023

    Leukemia, Myeloid, Acute Trial in Japan (Quizartinib)

    Completed
    Has Results
    • Leukemia, Myeloid, Acute
    • Aichi, Japan
    • +26 more
    Feb 4, 2020

    FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia Trial in Wuhan (T cell injection targeting FLT3 chimeric antigen

    Recruiting
    • FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
    • T cell injection targeting FLT3 chimeric antigen receptor
    • Wuhan, Hubei, China
      Union Hospital, affiliated with TongJi Medical College, HuaZhong
    Jun 20, 2022

    AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)

    Not yet recruiting
    • AML, Adult
    • +4 more
    • Amiens, France
    • +19 more
    Sep 1, 2023

    Leukemia, Myeloid, Acute Trial in France (Ponatinib 30 MG)

    Recruiting
    • Leukemia, Myeloid, Acute
    • Ponatinib 30 MG
    • Angers, France
    • +13 more
    Aug 4, 2021

    AML, FLT3-ITD Mutation Trial in Hong Kong (Quizartinib, Omacetaxine Mepesuccinate Injection)

    Unknown status
    • AML
    • FLT3-ITD Mutation
    • Hong Kong, Hong Kong
      The University of Hong Kong
    Dec 9, 2020

    Acute Myeloid Leukemia Trial in Worldwide (Quizartinib, Intrathecal (IT) triple chemo prophylaxis, Fludarabine)

    Recruiting
    • Acute Myeloid Leukemia
    • Loma Linda, California
    • +36 more
    Feb 1, 2023

    Acute Myeloid Leukemia, Hematopoietic Stem Cell Transplantation Trial in Guangzhou (Sorafenib)

    Completed
    • Acute Myeloid Leukemia
    • Hematopoietic Stem Cell Transplantation
    • Guangzhou, Guangdong, China
      Department of Hematology,Nanfang Hospital, Southern Medical Univ
    Aug 21, 2019

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Duarte, Palo Alto, Houston (AMG 553)

    Not yet recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • AMG 553
    • Duarte, California
    • +2 more
    Dec 22, 2021

    Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)

    Recruiting
    • Relapsed or Refractory Acute Myeloid Leukemia (AML)
    • Suzhou, Jiangsu, China
      the First Affiliated Hospital of Soochow University
    Feb 6, 2022

    Acute Myeloid Leukemia Trial in Suzhou (anti-FLT3 CAR-T)

    Recruiting
    • Acute Myeloid Leukemia
    • anti-FLT3 CAR-T
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Dec 29, 2021

    B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

    Not yet recruiting
    • B7-H3-positive Relapsed/ Refractory Neuroblastoma
    • T cell injection targeting FLT3 chimeric antigen receptor
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute and Hospital
    Nov 1, 2022

    AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed

    Recruiting
    • AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
    • MRD-triggered arm
    • Prophylactic Arm
    • Heidelberg, BW, Germany
      University Hospital Heidelberg Med5
    Jan 4, 2021

    The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or

    Recruiting
    • Acute Leukemia
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • Guangzhou, Guangdong, China
      Department of Hematology,Nanfang Hospital, Southern Medical Univ
    Oct 28, 2022